semaglutide and heart problems Demonstrates Impressive Benefits – Even Before You Lose Weight Semaglutide in Cardiometabolic Diseases: SELECTing

% relative survival was normalized to vehicle controls (n = 4 technical replicates representative from 3 independent experiments)

Clinical data shows GI symptoms are most common early and decline noticeably with continued use

The trial data is the strongest evidence available for understanding how these medications perform

This means that detailed data specifically related to acid reflux, such as the severity of symptoms and the long-term effects on the esophageal lining, are limited

Months 4-6: Approaching Goals By mid-program, most Ponte Vedra Beach and Jacksonville patients have lost 10-15% of starting body weight, established healthier eating habits that feel sustainable, improved fitness and mobility, and normalized health markers (blood pressure, cholesterol, A1C)